|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Genmab A/S (GEN.CO) Release: Agreement for Daratumumab Receives Antitrust Clearance
9/24/2012 9:53:51 AM
COPENHAGEN, Denmark, Sept. 21, 2012 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that the worldwide license agreement for daratumumab with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has received antitrust clearance from the Federal Trade Commission and the Antitrust Division of the Department of Justice under the Hart-Scott-Rodino Act. This means that the license agreement has now become effective. A private placement prospectus containing details of the issue of new Genmab shares to Johnson & Johnson Development Corporation in connection with the agreement has been prepared in accordance with the applicable rules and regulations and filed with the Danish Financial Supervisory Authority. Upon the agency's approval, the new Genmab shares will be registered with the Danish Business Authority by way of a capital increase in Genmab and subsequently admitted to official listing and trading on the NASDAQ OMX Copenhagen A/S, after which the subscription agreement will be considered effective. The license agreement with Janssen Biotech, Inc. was first announced on August 30, 2012 (Company Announcements 20 and 21).
|
|
|
|
|
|
|
|
|
|
|